Ralph Weissleder

Ralph Weissleder is a professor at Harvard Medical School, director of the Center for Systems Biology at Massachusetts General Hospital (MGH) and an attending interventional radiologist at MGH.

Weissleder graduated from University of Heidelberg in 1985. Following his degrees, Weissleder completed an Internship and residency at University Hospital, Monterrey, Mexico. Weissleder pursued his post-doctoral research (1986–1989) and clinical training in radiology at Massachusetts General Hospital (MGH) and at Harvard Medical School (HMS). In 1994, Weissleder became assistant professor at HMS, full professor in 2001 (Department of Radiology), and an active physician (interventional radiology) at Massachusetts General Hospital. In 2007, Weissleder was appointed director of the MGH Center for Systems Biology and in 2008, he was also appointed professor in systems biology at HMS. Weissleder is a member of the Dana-Farber/Harvard Cancer Center.

Weissleder has received honorary degrees from The Universidad Autonoma de Nuevo León, Mexico (2007) and from Harvard University (2001).

Dr. Weissleder is a researcher in biotechnology, especially in the fields of imaging and next-gen diagnostics.^[1] His research interests include the development of molecular imaging techniques, tools for early disease detection as well as the development of nanomaterials for sensing and systems analysis.^[2] His research is translational in nature and several of his developments have led to commercialized technologies and advanced clinical trials. He is cofounder of T2 Biosystems, Lumicell, Accure Health, VisEn Medical (acquired by Perkin Elmer), and an advisor to several other biotech companies (Moderna, Seer Bioscience, Boston Scientific).